

ASX Announcement

12 June 2026

Peer-Reviewed Publication Demonstrates Localised Distribution of OncoSil™ Microparticles in Pancreatic Cancer Tissue

Sydney, Australia – 12 June 2026: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), is pleased to announce the publication of new peer-reviewed histopathological findings in *Pathology International*, providing further evidence supporting the mechanism of action and localised therapeutic effect of the OncoSil™ device in patients with unresectable LAPC.

The study was conducted by investigators from the Royal Adelaide Hospital and the University of Adelaide and was published in *Pathology International*, a peer-reviewed international pathology journal.

The publication prospectively examined surgical specimens from patients with LAPC who had received EUS-guided OncoSil™ microparticles implantation plus chemotherapy prior to surgical resection of the tumour. Median overall survival from chemotherapy commencement in the eight patients where histopathological analysis was undertaken was **24 months**.

The publication is titled: *"Histopathological examination of pancreatectomy specimens from patients with locally advanced pancreatic adenocarcinoma following endoscopic ultrasound-guided phosphorus-32 (³²P) implantation and chemotherapy¹"*

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"This publication provides important histopathological evidence that implanted Phosphorus-32 microparticles remain confined within tumour tissue, supporting the highly localised mechanism of action of the OncoSil™ device. The findings provide further scientific validation of the technology and add to the growing body of evidence supporting its use in pancreatic cancer treatment.

We congratulate Dr Amanda Lim and her co-investigators at the Royal Adelaide Hospital and the University of Adelaide on this important contribution to the pancreatic cancer literature and thank them for their continued commitment to advancing the understanding of OncoSil™ therapy."

Key Findings

- Histopathological examination confirmed the presence of OncoSil™ microparticles within tumour tissue in all evaluated specimens.
- No evidence of migration of OncoSil™ microparticles was observed beyond the tumour implantation site.
- No OncoSil™ microparticles were identified within surrounding healthy pancreatic tissue, blood

vessels, lymphatic vessels, adjacent lymph nodes or nearby organs.

- Findings support the highly localised delivery of beta radiation directly to tumour tissue while minimising exposure to surrounding healthy tissue.
- The study provides pathological evidence supporting the favourable retention characteristics of the OncoSil™ device and its potential safety advantages.
- Researchers concluded that the observed distribution profile may support optimisation of future dosing and implantation strategies to further enhance therapeutic effect.

The publication represents the first reported histopathological evaluation of the distribution of implanted OncoSil™ microparticles and their decayed forms in surgically resected pancreatic cancer specimens.

Importantly, the findings demonstrated that implanted radioactive microparticles remained confined to the tumour site, supporting the intended localised mechanism of action of the OncoSil™ device. The authors noted that this characteristic is expected to maximise therapeutic impact while minimising systemic and peri-tumour adverse effects.

The study further suggests that future investigations may explore increased dose density and additional implantation sites within larger tumours to potentially optimise clinical outcomes.

For more information on the release on Investor Hub please see: <https://investors.oncosil.com/link/yzYQxP>

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 160 96424981	Mr. Tim Luscombe & Ms. Nova Taylor Joint Company Secretaries E: tim.luscombe@bio101.com & nova.taylor@bio101.com T: +61 429 707 079 & +61 414 877 703
---	--

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical's mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (³²P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year². Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Australia, Türkiye and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Germany, Greece, Türkiye, Portugal, Israel and the UK.

To learn more, please visit: www.oncosil.com/

1. Lim AH, A. Ruzskiewicz A, Rodgers N et al. Histopathological examination of pancreatectomy specimens from patients with locally advanced pancreatic adenocarcinoma following endoscopic ultrasound-guided phosphorus-32 (³²P) implantation and chemotherapy. Pathology International 2026; 76: e70131. doi: 10.1111/pin.70131
2. <https://gco.iarc.fr/en>